ClinicalTrials.gg
CompletedNCT04090710CYTOSHRINKUpdated Aug 28, 2026

SBRT With Combination Ipilimumab/Nivolumab for Metastatic Kidney Cancer

A Phase 2 interventional study of Ipilimumab/ Nivolumab and SBRT + Ipilimumab/Nivolumab in Metastatic Renal Cell Carcinoma, sponsored by Ontario Clinical Oncology Group (OCOG). Completed at 7 sites in 2 countries. Per ClinicalTrials.gov, last updated 2026-08-28.

Sponsored by Ontario Clinical Oncology Group (OCOG) · Phase 2, Interventional, and Treatment

How we know · 4 judgments

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
66
Allocation
Randomized
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 160 studies in Carcinoma, Renal Cell with a site in Canada — 10 open to participants now, 29 under way, 10 of them phase 3. Carcinoma, Renal Cell · Canada.

Enrollment
87th of 142
66 · median 128
Started
2020
with 16 others
Phase 2
37 of 160
2 open now
Registered
116th of 160
by date

Among the 160 studies in Carcinoma, Renal Cell with a site in Canada, this one is the 87th largest by enrollment of the 142 interventional ones that give a count, is one of 17 that started in 2020, is one of 37 in phase 2, and was the 116th registered.

Carcinoma, Renal Cell

2,043 studies on the registry are indexed under Carcinoma, Renal Cell; 395 are open to participants now.

Browse Carcinoma, Renal Cell studies →

Open to participants now

10 of the 160 studies in Carcinoma, Renal Cell with a site in Canada are open now. Recruiting first, the newest first:

5 more — sign in →

All 10 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 308 Carcinoma, Renal Cell studies recruiting now, 255 (83%) set no upper age limit and 18 (6%) stop at 75 or younger; 21 take children under 18; 20 take healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 160 studies in Carcinoma, Renal Cell with a site in Canada, or all of them as a file.
02

Study summary

This trial will evaluate the addition of cytoreductive stereotactic body radiation therapy (SBRT) to standard of care combination ipilimumab and nivolumab (I/N) versus I/N alone for the treatment of metastatic kidney cancer.

Read the detailed description

This is a multi-centre, open label, phase II randomized clinical trial evaluating SBRT as upfront cytoreductive therapy to the primary renal mass along with combination I/N therapy in patients with intermediate/poor risk mRCC who are not candidates for cytoreductive nephrectomy. Eligible and consenting, newly diagnosed and histologically confirmed intermediate/poor risk mRCC patients based on IMDC criteria with primary disease in-situ will be randomized in a 2:1 fashion to either induction I/N followed by SBRT prior to the second cycle (experimental arm) versus I/N alone (standard arm). Patients will be stratified based on IMDC criteria (intermediate 1-2 versus poor 3-6).

  • Standard Arm: induction ipilimumab 1 mg/kg combined with nivolumab 3 mg/kg (I/N) every 3 weeks for cycles 1-4 followed by maintenance treatment with nivolumab 240mg every 2 weeks or 480mg every 4 weeks until disease progression (as determined by RECIST 1.1), intolerance, or patient/physician decision to stop treatment.
  • Experimental Arm: induction ipilimumab 1 mg/kg combined with nivolumab 3 mg/kg (I/N) every 3 weeks for one cycle, followed by SBRT to the primary disease in-situ, prior to cycle 2-4 of I/N. Patients randomized to SBRT will undergo radiation planning during the first cycle of I/N to their primary kidney mass, and then the radiation will be delivered between cycles 1 and 2 to a dose of 30-40 Gy in 5 fractions every other day over 1.5 weeks. Approximately one week following completion of SBRT, patients will start cycle 2 of I/N as per standard of care. The total time elapsed between the start of cycle 1 and 2 of I/N should be no more than 6 weeks. After completion of up to four cycles of I/N, patients will proceed to standard of care maintenance treatment with nivolumab 240mg every 2 weeks or 480mg every 4 weeks until disease progression (as determined by RECIST 1.1), intolerance, or patient/physician decision to stop treatment.

During treatment (standard and experimental arm) participants will be assessed for radiation toxicity and the occurrence of adverse events. Following treatment, participants will be assessed at a clinic visit every 3 months, for a period of 1 year. Progression free survival will be assessed by CT scan (chest; abdomen and pelvis), which is performed after the final I/N treatment and every 3 months as per standard of care. Participants will be followed for one additional year, seen at 18 and 24 months to assess survival. The planned sample size is 78 study participants.

03

Conditions studied

  • Metastatic Renal Cell Carcinoma

Keywords

  • SBRT
  • Ipilimumab
  • Nivolumab
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. proven renal cell carcinoma of any histology.
  2. Imaging proven disease based on CT or MRI within 10 weeks of screening.
  3. Intermediate/poor risk disease based on IMDC criteria (see Appendix II).
  4. Primary kidney lesion amenable to SBRT.
  5. Eligible for standard of care delivery of ipilimumab and nivolumab (I/N) according to approved product monograph.

Exclusion criteria

Exclusion Criteria:

  1. A maximum primary renal lesion size of 20 cm or greater.
  2. Candidate for cytoreductive nephrectomy, unless a patient has refused cytoreductive nephrectomy (in this case, a discussion of cytoreductive nephrectomy and patient refusal must be documented).
  3. Treatment with prior systemic therapy in the or setting for renal cell carcinoma.
  4. Previous abdominal radiation precluding SBRT.
  5. Kanofsky Performance () score below 60 (see Appendix III).
  6. History of auto-immune disorder precluding treatment with ipilimumab or nivolumab.
  7. History of ataxia telangiectasia or other radiation sensitivity disorders.
  8. Chronic use or other chronic immune suppressive therapy. (Participants are permitted the use of topical, ocular, intra-articular, intranasal, and inhalational corticosteroids (with minimal systemic absorption). Adrenal replacement steroid doses of prednisone ≤ 10 mg daily are permitted).
  9. Use of medicinal herbal preparations (not including medical cannabis) unless prescribed by a treating physician.
  10. Inability to lie flat for at least 30 minutes without moving.
  11. Pregnant or lactating women.
  12. Geographic inaccessibility for follow-up.
  13. Inability to provide .
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
66 participants (actual)

Study arms

  • Active comparator
    Standard of Care I/N alone

    induction ipilimumab 1 mg/kg combined with nivolumab 3 mg/kg (I/N) every 3 weeks for cycles 1-4 followed by maintenance treatment with nivolumab 240mg every 2 weeks or 480mg every 4 weeks until disease progression (as determined by RECIST 1.1), intolerance, or patient/physician decision to stop treatment.

    Drug: Ipilimumab/ Nivolumab

  • Experimental
    Standard of Care I/N plus primary disease SBRT

    induction ipilimumab 1 mg/kg combined with nivolumab 3 mg/kg (I/N) every 3 weeks for one cycle, followed by SBRT to the primary disease in-situ, prior to cycle 2-4 of I/N. Patients randomized to SBRT will undergo radiation planning during the first cycle of I/N to their primary kidney mass, and then the radiation will be delivered between cycles 1 and 2 to a dose of 30-40 Gy in 5 fractions every other day over 1.5 weeks. Approximately one week following completion of SBRT, patients will start cycle 2 of immunotherapy as per standard of care. The total time elapsed between the start of cycle 1 and 2 of I/N should be no more than 6 weeks. After completion of up to four cycles of I/N, patients will proceed to standard of care maintenance treatment with nivolumab 240mg every 2 weeks or 480mg every 4 weeks until disease progression (as determined by RECIST 1.1), intolerance, or patient/physician decision to stop treatment.

    Radiation: SBRT + Ipilimumab/Nivolumab

Interventions

  • DrugIpilimumab/ Nivolumab

    induction ipilimumab 1 mg/kg combined with nivolumab 3 mg/kg (I/N) every 3 weeks for cycles 1-4 followed by maintenance treatment with nivolumab 240mg every 2 weeks or 480mg every 4 weeks until disease progression

    Also known as: Yervoy/Opdivo

  • RadiationSBRT + Ipilimumab/Nivolumab

    SBRT to the primary disease in-situ, prior to cycle 2-4 of I/N. Patients randomized to SBRT will undergo radiation planning during the first cycle of I/N to their primary kidney mass, and then the radiation will be delivered between cycles 1 and 2 to a dose of 30-40 Gy in 5 fractions every other day over 1.5 weeks.

This study also gives NivolumabStudies of NivolumabNivolumab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record., IpilimumabStudies of IpilimumabIpilimumab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.. No intervention listed here names it: that was found by reading the record.

06

What researchers measure

Primary outcomes

  1. Progression free survival (PFS)

    The primary outcome of this study is the hazard ratio for progression-free survival (PFS), defined from the date of randomization until the date of progression (PFS truncated at subsequent systemic therapy) as determined by RECIST 1.1, or death due to any cause, whichever comes first. All attempts will be made to follow-up patients for the primary outcome measure for at least one year, even if a patient stops treatment. Patients who do not have a primary outcome event at the time of analysis will be censored on the last date the patient can be confirmed as alive and progression-free.

    Time frame: 2 years

Secondary outcomes

  1. Subject safety

    Incidence and attribution of deaths

    Time frame: Date of randomization until 1year post treatment

  2. Overall Survival

    • Overall survival, defined from the date of randomization to the date of death due to any cause. Patients with no known death date at the time of analysis will be censored on the last date they are confirmed alive.

    Time frame: 2 years

  3. Objective response rate

    • Objective response rate, which is defined as the proportion of randomized subjects who achieve a best response of complete response (CR) or partial response (PR) using the RECIST 1.1 criteria.

    Time frame: 1 year

  4. Quality of Life: EORTC QLQ-C30 questionnaire

    • Quality of life, which will be evaluated using the EORTC QLQ-C30 questionnaire.

    Time frame: 1 year

  5. Subject safety

    Number of Adverse Events and Serious Adverse Events using NCI CTCAE v5.0

    Time frame: 1 Year

  6. Ipilimumab/ Nivolumab drug tolerability

    Ipilimumab/Nivolumab treatment discontinuation rates

    Time frame: From the date of randomization until date of first documented disease progression up to 1 year.

  7. Ipilimumab/ Nivolumab drug tolerability

    Number of doses of Ipilimumab/Nivolumab combination treatment

    Time frame: From the date of randomization until date of first documented disease progression, up to 1 year.

  8. Ipilimumab/ Nivolumab drug tolerability

    Number of Nivolumab maintenance doses

    Time frame: From the date of randomization until date of first documented disease progression, up to 1 year.

  9. Ipilimumab/ Nivolumab drug tolerability

    Time to treatment discontinuation from the date of randomization

    Time frame: From the date of randomization until date of first documented disease progression, up to 1 year.

Other outcomes

  1. Exploratory Outcomes: Evaluation of baseline and changes during treatment in blood immune signatures

    Changes in blood immune signatures through interrogation of circulating blood biomarkers.

    Time frame: 1 year

  2. Exploratory Outcomes: Evaluation of baseline and changes during treatment in stool microbiome

    Changes in stool microbiome using 16S RNA.

    Time frame: 1 year

  3. Correlation with blood or stool immune signatures

    Tumor tissue analysis using immunohistochemistry

    Time frame: 1 year

07

Study locations

7 sites
  • Peter MacCallum Cancer Centre
    Melbourne, 3000, Australia
  • Cross Cancer Institute
    Edmonton, Alberta T6G 1Z2, Canada
  • Juravinski Cancer Centre
    Hamilton, Ontario, Canada
  • Grand River Regional Cancer Centre
    Kitchener, Ontario N2G1G3, Canada
  • London Regional Cancer Centre
    London, Ontario N2G1G3, Canada
  • The Ottawa Regional Cancer Centre
    Ottawa, Ontario K1H8L6, Canada
  • Sunnybrook Health Sciences Centre- Odette Cancer Centre
    Toronto, Ontario M4N3M5, Canada
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2020 to primary completion in Apr 2026, 74 months.

Of 185 non-industry phase 2 interventional studies under Carcinoma, Renal Cell, half reached primary completion within 67 months of starting (the median), counting those still running; a quarter within 40 and three quarters within 98. This study's 74 months is above that.

Counting every sponsor, half of 232 studies reached it within 58 months; a quarter within 33 and three quarters within 94.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 9, 2019
First posted
Sep 16, 2019
StartActual
Jan 29, 2020
Primary completionActual
Apr 23, 2026
CompletionActual
Jun 30, 2026
Last update
Aug 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 28, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04090710
Lead sponsor
Ontario Clinical Oncology Group (OCOG)
Responsible party
Sponsor
First posted
Sep 16, 2019
Start date
Jan 29, 2020
Primary completion
Apr 23, 2026
Completion
Jun 30, 2026
Last update
Aug 28, 2026

Study contacts

Aly-Khan Lalani, MD
principal investigator · Juravinski Cancer Centre

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion